Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 3/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30557259 | 0.98 | AXL (0.43) | AXLNUDT1TYRRIPK1BRD4 | |
| SCHEMBL588819 | 0.73 | ALDH1A1 (0.39) | KDM4EALDH1A1 | |
| SCHEMBL1334813 | 0.71 | AXL (0.45) | AXLNUDT1BRD4APPMAPK1 | |
| SCHEMBL4063067 | 0.71 | AXL (0.45) | AXLNUDT1TYRRIPK1BRD4 | |
| SCHEMBL29362558 | 0.71 | MAPK1 (0.45) | AXLNUDT1BRD4APPMAPK1 | |
| SCHEMBL343400 | 0.71 | ADORA2A (0.57) | AXLNUDT1BRD4APPMAPK1 | |
| SCHEMBL414134 | 0.71 | MAPK1 (0.45) | AXLNUDT1BRD4APPMAPK1 | |
| SCHEMBL684703 | 0.71 | AXL (0.45) | AXLNUDT1RIPK1BRD4APP | |
| SCHEMBL12798351 | 0.71 | AXL (0.45) | AXLNUDT1TYRRIPK1BRD4 | |
| SCHEMBL29365560 | 0.71 | AXL (0.45) | AXLNUDT1RIPK1BRD4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814360-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | claimed |
| EP-3814360-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | claimed |
| EP-4415817-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-116621860-A | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-111511748-B | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| WO-2023064349-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| CN-101133056-A | Antitumor compounds | NAT HEALTH RESEARCH INSTITUTES (CN) | 2008-02-27 | — | — | CN | disclosed |
| EP-1838711-A2 | ANTI-TUMOR COMPOUNDS | National Health Research Institutes (TW) | 2007-10-03 | — | — | EP | disclosed |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| EP-1732546-A2 | NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2006-12-20 | — | — | EP | disclosed |
| US-20060183758-A1 | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans | CB RESEARCH AND DEVELOPMENT, INC. (US) | 2006-08-17 | — | — | US | disclosed |
| WO-2006074041-A2 | ANTI-TUMOR COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148801-A1 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-06 | — | — | US | disclosed |
| WO-2005095399-A2 | NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | AXL 3934/4885NUDT1 962/4885TYR 1789/4885 |
| US-20060183758-A1 | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans | TPMT, INMT, AANAT | AXL 2823/4885NUDT1 21/4885TYR 115/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | AXL 3381/4885NUDT1 463/4885TYR 4159/4885 |
| US-20060148801-A1 | Anti-tumor compounds | TUBB1, TUBB3, TUBB | AXL 2506/4885NUDT1 3520/4885TYR 202/4885 |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | AXL 1433/4885NUDT1 3188/4885TYR 1553/4885 |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | AXL 4798/4885NUDT1 1016/4885TYR 242/4885 |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | MAP3K19, MAP4K2, MAP3K1 | AXL 290/4885NUDT1 2531/4885TYR 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.